The potential of three-dimensional cell culture models is now well-recognised by scientists; however, there are still some challenges. Margaritha Mysior and Jeremy Simpson address some of the common challenges of working with spheroids and organoid models – including how they are developed and how to obtain high-resolution, high-content images and…
List view / Grid view
An assay is an analytical procedure in laboratory medicine, pharmacology and molecular biology for measuring the activity of a target entity.
Scientists from LifeArc, an independent medical research charity in the UK, explain how they’re using the latest imaging technologies to progress drug discovery campaigns and identify the most promising candidates for antibody-based therapies.
Native mass spectrometry has the potential to be a fast, simple, highly sensitive and automatable technique for compound screening in drug design and discovery. In this article, Rod Chalk and Nicola Burgess-Brown discuss the key attributes of native mass spectrometry and reasons why it is not yet widely employed.
Application note: Detection of anti-drug antibody (ADA) using single molecule counting (SMCTM) technology
11 June 2019 | By Merck
All biological therapeutics have the potential to induce an immunemediated response ranging from benign to severe adverse effects.
Image-based phenotypic profiling of small molecules has been used for identification and characterisation of small molecules in drug discovery and can provide important insights into their mechanisms of action (MOA). This article discusses the use of phenotypic profiling in drug discovery and how machine-learning algorithms could help improve objectivity, processing…
23 May 2019 | By Sartorius
Immunotherapy for cancers involves artificially prompting the immune system to treat cancer. Many cancer cells have surface tumour antigen molecules, which can be detected by the immune system’s antibody proteins, which bind to the antigen.
16 May 2019 | By
Researchers say they have affirmed inconsistencies in the use of a common laboratory procedure called immunohistochemical staining.
Typically, early drug discovery campaigns start with the screening of chemical libraries to identify candidate chemotypes modulating a particular target and/or phenotype. Success of the primary screening depends on multiple factors related to both biology and chemistry. These include the target’s druggability, sensitivity and specificity of assay system, composition and…
1 May 2019 | By Taconic Biosciences
Ensure reproducibility with TruBIOME™ - the unique approach to generating research model colonies, which allows you complete control over their microbiome, from conception to cohort delivery.
20 April 2019 | By Pradeep Sacitharan
Osteoarthritis (OA) is a painful and debilitating disease of articular joints.1,2 Its clinical prevalence is as high as 21.6 percent of the population in the United States,3 which constitutes direct health costs of over 80 billion US dollars annually.4
The landscape of cancer treatment has changed dramatically in the last seven years, beginning with the approval of Ipilmumab in 2011, the first immunotherapy drug. Efforts to unsheathe the tumour cells of their protective microenvironment and expose them to an active immune response have delivered several monoclonal antibodies (mAbs) that…
The importance of characterising chemical starting points of drugs using appropriate in vitro ADME-toxicity assays
Over the past 30 years, one strategy the pharmaceutical industry has adopted in the drug discovery process has been to “fail early, fail often”.1,2 As most molecules in the early stages of drug discovery will have sub-optimal characteristics, significant modification is necessary to improve their properties.
21 March 2019 | By NanoTemper Technologies
Current technologies that measure molecular interactions for drug discovery slow down and complicate screening. Dianthus is the answer to the demands for fast, non-stop, highly sensitive hit identification, hit validation and lead optimisation.